These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11748972)

  • 1. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Plaxe SC; Blessing JA; Husseinzadeh N; Webster KD; Rader JS; Dunton CJ
    Gynecol Oncol; 2002 Feb; 84(2):241-4. PubMed ID: 11812081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Olt G; Husseinzadah N; Lentz SS; DeGeest K; Valea FA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):151-4. PubMed ID: 12172981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Hoffman MA; Blessing JA; Nuñez ER
    Gynecol Oncol; 2001 Jun; 81(3):433-5. PubMed ID: 11371134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
    Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
    Albain KS; Liu PY; Hantel A; Poplin EA; O'Toole RV; Wade JL; Maddox AM; Alberts DS
    Gynecol Oncol; 1995 Jun; 57(3):407-11. PubMed ID: 7774846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
    Lee HP; Seo SS; Ryu SY; Kim JH; Bang YJ; Park SY; Nam JH; Kang SB; Lee KH; Song YS
    Gynecol Oncol; 2008 Jun; 109(3):359-63. PubMed ID: 18405948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
    Fracasso PM; Blessing JA; Morgan MA; Sood AK; Hoffman JS
    J Clin Oncol; 2003 Aug; 21(15):2856-9. PubMed ID: 12885801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Miller DS; Blessing JA; Waggoner S; Schilder J; Sorosky J; Bloss J; Schilder R
    Gynecol Oncol; 2005 Jan; 96(1):67-71. PubMed ID: 15589582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
    Zalupski MM; Philip PA; LoRusso P; Shields AF
    Cancer Chemother Pharmacol; 1997; 40(3):225-7. PubMed ID: 9219505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Morgan MA; Carlson J;
    Am J Clin Oncol; 2002 Feb; 25(1):45-7. PubMed ID: 11823695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; McMeekin DS
    Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.